Oklo’s Groves Becomes Fifth DOE Pilot Reactor to Reach Criticality, First on Private Land
Oklo said its Groves low-power isotope test reactor in Lockhart, Texas reached criticality Aug. 5 at 9:19 p.m. ET, becoming the fifth reactor to do so under the U.S. DOE Reactor Pilot Program and the first on private land. Groves is authorized up to 100 We but will not run at that level; testing continues to verify reactor behavior. Oklo links the milestone to future isotope production.
How this was made
The 30-second read
Why it matters
Reaching criticality is a key technical gate for reactor commissioning and operational readiness, which can improve odds of progressing to larger-scale isotope production facilities and related regulatory steps.
Market read
This is a fresh execution milestone for Oklo’s reactor platform, likely supportive for sentiment around private advanced nuclear and isotope production timelines.
What to watch
The article notes startup testing continues and that future NRC licensing for separate foundry projects is not automatic, so regulatory and schedule risk remains for the commercial pathway.
Background
Groves is Oklo’s low-power isotope test reactor under the DOE Reactor Pilot Program, tied to Oklo Isotopes after its 2024 acquisition of Atomic Alchemy.
Ticker impact
Oklo’s Groves reactor reached criticality Aug. 5 under the DOE Reactor Pilot Program, the first on private land, supporting its isotope-production roadmap.
Near-term sentiment tailwind for OKLO on execution credibility; magnitude likely limited until commercial isotope production or major licensing milestones are disclosed.
The article is a fresh, company-specific DOE milestone (first private-land RPP criticality) and links Groves to Oklo Isotopes’ future foundry and NRC-licensed lab. However, it explicitly says Groves will not produce saleable isotopes and is focused on testing, which tempers immediate revenue implications.
Market effects
Adds a concrete execution datapoint for private, non-national-lab advanced reactor development under DOE’s RPP, potentially improving perceived feasibility for isotope-focused nuclear startups.
Texas siting on private land may support investor confidence in non-federal deployment models.
Strengthens the US domestic isotope production narrative, which can influence broader nuclear supply-chain and medical isotope investment sentiment.
Counterpoint
Because Groves is explicitly a low-power test reactor that will not produce saleable isotopes, the milestone may not translate into near-term cash flows or measurable commercial progress.
Key entities
- companyOklo
Developer of the Groves isotope test reactor and operator of the broader isotope production strategy.
- government_programU.S. Department of Energy (DOE) Reactor Pilot Program
Program under which multiple advanced reactors have achieved criticality this summer.
- business_unitOklo Isotopes
Oklo’s isotope business formed from the Atomic Alchemy acquisition, including an NRC-licensed Idaho radiochemistry lab.
